KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Current Assets (2016 - 2025)

Boston Scientific's Current Assets history spans 17 years, with the latest figure at $8.8 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 27.08% year-over-year to $8.8 billion; the TTM value through Dec 2025 reached $8.8 billion, up 27.08%, while the annual FY2025 figure was $8.8 billion, 27.08% up from the prior year.
  • Current Assets for Q4 2025 was $8.8 billion at Boston Scientific, up from $8.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $8.8 billion in Q4 2025 and bottomed at $5.1 billion in Q1 2022.
  • The 5-year median for Current Assets is $6.4 billion (2021), against an average of $6.5 billion.
  • The largest annual shift saw Current Assets dropped 16.98% in 2022 before it rose 27.08% in 2025.
  • A 5-year view of Current Assets shows it stood at $6.3 billion in 2021, then dropped by 8.82% to $5.8 billion in 2022, then rose by 13.09% to $6.5 billion in 2023, then grew by 6.23% to $6.9 billion in 2024, then grew by 27.08% to $8.8 billion in 2025.
  • Per Business Quant, the three most recent readings for BSX's Current Assets are $8.8 billion (Q4 2025), $8.0 billion (Q3 2025), and $7.1 billion (Q2 2025).